NCT03028116View on ClinicalTrials.gov

Reactogenicity, Safety and Immunogenicity Study of a Allantoic Split Inactivated Seasonal Influenza Vaccine

PHASE1CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

May 31, 2016

Primary Completion Date

June 30, 2016

Study Completion Date

July 31, 2016

Conditions
Influenza, Human
Interventions
BIOLOGICAL

influenza vaccine

"A allantoic split inactivated seasonal influenza vaccine has been prepared on eggs and is made from inactivated parts of the following influenza virus strains:~NIBRG-121xp (A/California/7/2009 (H1N1)v and А/PR/8/34 (H1N1)), NYMC X-217 (A/Victoria/361/2011(H3N2) and А/PR/8/34 (H1N1)), NYMC BX-49 (B/Texas/06/2011 (Yamagata lineage) - like High Yield Reassortant (1:1:6) With B/Lee/40 NP, B/Panama/45/90 NS genes)."

BIOLOGICAL

Placebo

water for injection

Trial Locations (1)

050000

Kazakh National Medical University, Almaty

All Listed Sponsors
collaborator

Asfendiyarov Kazakh National Medical University

OTHER

collaborator

Research Institute of Influenza, Russia

OTHER

lead

Research Institute for Biological Safety Problems

OTHER_GOV

NCT03028116 - Reactogenicity, Safety and Immunogenicity Study of a Allantoic Split Inactivated Seasonal Influenza Vaccine | Biotech Hunter | Biotech Hunter